RRP45 Antibody

What is RRP45 and what is its role in the RNA exosome complex?

RRP45 (also called Exosome component 9, P5, P6, Pm/scl-75, Pmscl1, or Rrp45p) is one of the six PH-like subunits that form the lower ring of the RNA exosome complex. The 10-subunit RNA exosome complex consists of three S1/KH cap subunits (human EXOSC2/3/1; yeast Rrp4/40/Csl4), six PH-like subunits including RRP45/EXOSC9 (human EXOSC4/7/8/9/5/6; yeast Rrp41/42/43/45/46/Mtr3), and a singular 3′-5′ exo/endonuclease DIS3/Rrp44 . This highly conserved molecular machine processes and degrades numerous coding and non-coding RNAs, making it essential for RNA metabolism across eukaryotes. The precise arrangement of these subunits creates a barrel-like structure with a central channel through which RNA substrates pass during processing.

What types of RRP45 antibodies are commercially available for research?

Commercial RRP45 antibodies include affinity-isolated antibodies such as the Prestige Antibodies® HPA048257 and HPA041838 from Atlas Antibodies . These antibodies are predominantly produced in rabbits and are available in buffered aqueous glycerol solutions. When selecting an antibody, researchers should consider the specific application (Western blotting, immunoprecipitation, ChIP, immunofluorescence), the species reactivity, and the validated performance in peer-reviewed publications. While polyclonal antibodies offer broader epitope recognition, monoclonal antibodies provide higher specificity for particular epitopes.

How can I validate the specificity of my RRP45 antibody?

To validate RRP45 antibody specificity, implement a multi-step approach:

• Western blotting confirmation: First confirm that the antibody recognizes a protein of the expected molecular weight (~45-49 kDa for human RRP45). As demonstrated in studies of the RNA exosome, a specific Rrp40 antibody should recognize only the target protein under ChIP conditions .

• Knockdown/knockout controls: Use RRP45 knockdown or knockout cell lines as negative controls. Studies have successfully used shRNA to knock down other RNA exosome components (e.g., Rrp40) , and similar approaches can validate RRP45 antibodies.

• Immunoprecipitation followed by mass spectrometry: This can verify that the antibody pulls down RRP45 and its known interaction partners (other RNA exosome components).

• Cross-reactivity testing: Test the antibody against recombinant RRP45 protein alongside similar family members to assess potential cross-reactivity.

• Epitope mapping: Determine the specific region of RRP45 recognized by the antibody to better understand potential limitations in certain applications.

How should I optimize immunoprecipitation protocols using RRP45 antibodies?

For optimal immunoprecipitation (IP) with RRP45 antibodies, consider the following methodology:

• Cell lysis optimization: Use a gentle lysis buffer (e.g., 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA) supplemented with protease inhibitors to preserve protein complexes. RNA exosome studies have successfully used combinations of size chromatography, glycerol gradient sedimentation, and FLAG affinity purification to isolate protein complexes containing exosome components .

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody binding: Incubate cell lysates with RRP45 antibody overnight at 4°C with gentle rotation. Studies have shown successful immunoprecipitation of exosome components from various cell types, including primary B cells, CH12F3 B lymphoma cells, and Ramos B lymphoma cells .

• Beads addition and washing: Add protein A/G beads for 2-3 hours, followed by 4-5 washes with decreasing salt concentrations.

• Elution and validation: Elute the immunoprecipitated complex and confirm by Western blotting for both RRP45 and known interacting partners like other exosome components (Rrp40, Rrp46, Mtr3).

Multiple studies have successfully co-immunoprecipitated RNA exosome components with interacting partners, demonstrating that careful optimization can yield biologically meaningful results .

What are the best conditions for using RRP45 antibodies in ChIP experiments?

For chromatin immunoprecipitation (ChIP) with RRP45 antibodies:

• Crosslinking: Treat cells with 1% formaldehyde for 10 minutes at room temperature to crosslink protein-DNA complexes.

• Sonication optimization: Sonicate to generate DNA fragments of 200-500 bp, which is optimal for ChIP analysis.

• Antibody specificity confirmation: Always confirm antibody specificity under ChIP conditions using Western blotting, as demonstrated for Rrp40 antibodies in previous studies .

• Negative controls: Include IgG control and, ideally, a RRP45-depleted cell line to validate signal specificity.

• Positive controls: Include primers for regions known to have RNA exosome recruitment (e.g., switch regions in B cells for RNA exosome components) .

Research has shown that RNA exosome components like Rrp40 can be recruited to transcribed regions such as switch regions (Sμ and Sα) in activated B cells, and this recruitment can be quantified by ChIP followed by qPCR .

How can I effectively use RRP45 antibodies in immunofluorescence microscopy?

For optimal immunofluorescence with RRP45 antibodies:

• Fixation method selection: Test both paraformaldehyde (4%, 10-15 minutes) and methanol (-20°C, 10 minutes) fixation, as RRP45's nuclear localization may be better preserved with particular fixation methods.

• Permeabilization optimization: Use 0.2% Triton X-100 for 10 minutes, which generally provides good access to nuclear antigens.

• Blocking stringency: Block with 5% BSA or 5-10% normal serum from the secondary antibody species to minimize background.

• Primary antibody dilution series: Test a range of dilutions (1:100 to 1:1000) and incubation conditions (1 hour at room temperature versus overnight at 4°C).

• Co-staining strategy: Co-stain with markers of known RNA exosome localization sites (nucleolus, nuclear speckles) to validate the staining pattern.

• Signal amplification: Consider tyramide signal amplification for weak signals, particularly in tissues or when detecting endogenous levels.

• Controls: Include cells with RRP45 knockdown as negative controls and co-staining with antibodies against other exosome components for colocalization confirmation.

How can I investigate RRP45's role in specific RNA processing pathways?

To investigate RRP45's role in specific RNA processing pathways:

• Conditional depletion system: Establish an inducible knockdown or degron-tagged RRP45 system to avoid lethality associated with complete loss of essential RNA exosome components.

• RNA-seq after RRP45 depletion: Perform transcriptome-wide analysis to identify accumulated RNA species. Target validation can be performed by RT-qPCR on specific RNAs known to be exosome targets, such as pre-snRNAs, pre-ncRNAs, and snoRNAs, which have shown 9-20 fold increases in exosome mutant cells .

• CLIP-seq (UV crosslinking and immunoprecipitation): Use RRP45 antibodies for CLIP-seq to identify direct RNA targets bound by RRP45 in vivo.

• Genetic interaction screens: Combine RRP45 depletion with knockdown of other RNA processing factors to identify functional relationships.

• In vitro reconstitution: Use recombinant proteins to reconstitute partial or complete exosome complexes with or without RRP45 to assess biochemical activities.

RNA exosome dysfunction causes accumulation of specific RNA targets. For example, in cells with the disease-linked rrp41-L187P mutation, accumulation of U4 pre-snRNA, TLC1 pre-ncRNA, and U14 snoRNA was observed at levels 9-20 fold higher than controls .

What is known about RRP45's involvement in AID targeting and antibody diversification?

RRP45 and the RNA exosome complex play crucial roles in targeting AID (Activation-Induced cytidine Deaminase) during antibody diversification:

• Physical association: RNA exosome components, including RRP45 (Rrp45), have been found in protein complexes with AID through purification strategies combining size chromatography, glycerol gradient sedimentation, and affinity purification .

• Functional relevance in CSR: Knockdown of RNA exosome components (including Rrp40 and Mtr3) resulted in reduced class switch recombination (CSR) by 50-70% in B cells without affecting proliferation, AID expression levels, or germline transcription .

• Recruitment to switch regions: ChIP experiments have demonstrated that RNA exosome components are recruited to transcribed switch regions (Sμ and Sα) in activated B cells .

• AID dependency: Interestingly, the recruitment of RNA exosome components (like Rrp40) to switch regions appears to be AID-dependent, as this recruitment was not observed in AID-deficient B cells .

• Model of function: The RNA exosome is thought to resolve RNA-DNA hybrids (R-loops) formed during transcription of switch regions, thereby exposing single-stranded DNA for AID-mediated deamination.

This research highlights a specialized role for the RNA exosome in adaptive immunity, beyond its general RNA processing functions.

How can I study disease-associated mutations affecting RRP45 and the RNA exosome?

To study disease-associated mutations in RRP45 and other RNA exosome components:

• Model system selection: The yeast Saccharomyces cerevisiae offers an excellent model system due to the high conservation of the RNA exosome complex. Disease-linked mutations can be modeled in orthologous yeast genes, as demonstrated for an EXOSC2 patient mutation that was successfully modeled in the yeast RRP4 gene .

• Cell line engineering: Use CRISPR-Cas9 to introduce specific mutations into human cell lines to study their effects on exosome assembly and function.

• Patient-derived materials: Where available, study cells from patients with RNA exosome mutations to assess naturally occurring dysfunction.

• Functional assays: Assess:

  • RNA processing defects using targeted RT-qPCR of known exosome substrates

  • Protein-protein interactions via co-immunoprecipitation

  • Complex assembly using glycerol gradient sedimentation

  • Cellular localization through immunofluorescence microscopy

• Structural biology approaches: Utilize cryo-EM or X-ray crystallography to understand how specific mutations affect complex architecture.

Disease-linked mutations in RNA exosome components have been identified in patients with various conditions, including multiple myeloma. For example, a missense mutation resulting in the p.Met40Thr substitution in EXOSC2 was found to potentially disrupt the interaction between the RNA exosome and the essential RNA helicase MTR4 .

What approaches can be used to study interactions between RRP45 and RNA exosome cofactors?

To investigate interactions between RRP45 and RNA exosome cofactors:

• Proximity-based labeling: Use BioID or APEX2 fused to RRP45 to identify proteins in close proximity in living cells.

• Co-immunoprecipitation with crosslinking: Utilize chemical crosslinking to stabilize transient interactions before immunoprecipitation with RRP45 antibodies.

• Yeast two-hybrid screening: Screen for direct protein-protein interactions using RRP45 as bait.

• Structural approaches: Employ cryo-EM to visualize complexes containing RRP45 and its cofactors.

• In vitro reconstitution: Recombinantly express and purify RRP45 and potential interaction partners to assess direct binding and functional effects.

• Genetic interaction mapping: Use synthetic genetic array (SGA) analysis in yeast or CRISPR screens in mammalian cells to identify functional relationships.

Critical interactions have been identified between RNA exosome components and cofactors. For example, the Met40 residue in EXOSC2 (a cap subunit of the RNA exosome) is thought to make direct contact with the essential RNA helicase MTR4, potentially stabilizing this critical interaction .

What are common issues with RRP45 antibody specificity and how can they be addressed?

Common specificity issues with RRP45 antibodies and their solutions include:

• Cross-reactivity with related proteins: The RNA exosome contains multiple structurally similar PH-domain subunits that may cross-react with RRP45 antibodies. Solution: Validate antibody specificity using knockout/knockdown controls, and consider epitope-tagged RRP45 as an alternative approach.

• Recognition of unexpected isoforms: Alternative splicing may generate RRP45 isoforms with different antibody reactivity. Solution: Use multiple antibodies targeting different epitopes to ensure comprehensive detection.

• Post-translational modifications blocking epitopes: Modifications might interfere with antibody binding. Solution: Test multiple antibodies targeting different regions and consider dephosphorylation or other treatments before analysis.

• Conformational epitopes lost in denaturation: Some antibodies recognize three-dimensional structures disrupted in Western blotting. Solution: Test native conditions for immunoprecipitation and use alternative antibodies for denatured applications.

• Batch-to-batch variability: This is particularly common with polyclonal antibodies. Solution: Validate each new lot against previous lots using positive controls and standardized protocols.

Careful validation using both positive and negative controls is essential for ensuring antibody specificity and reliability in experimental settings.

How can I optimize RRP45 antibody performance in Western blotting?

For optimal Western blotting with RRP45 antibodies:

• Sample preparation optimization:

  • Add RNase inhibitors to lysis buffers to prevent RNA-dependent protein interactions from dissociating

  • Include phosphatase inhibitors as phosphorylation may affect epitope recognition

  • Test both reducing and non-reducing conditions

• Gel percentage selection: Use 10-12% gels for optimal resolution of RRP45 (~45-49 kDa).

• Transfer optimization:

  • For PVDF membranes: Use 20% methanol in transfer buffer

  • For nitrocellulose: Consider adding 0.1% SDS for more efficient transfer of hydrophobic proteins

• Blocking optimization: Test both 5% milk and 5% BSA as blocking agents, as some antibodies perform better with one versus the other.

• Antibody dilution and incubation: Test a range of dilutions (1:500 to 1:5000) and incubation conditions (1 hour at room temperature versus overnight at 4°C).

• Signal development: For weak signals, consider using enhanced chemiluminescence (ECL) substrates with higher sensitivity or switch to fluorescent secondary antibodies for more quantitative analysis.

• Positive controls: Include lysates from cells known to express RRP45 at high levels (e.g., rapidly dividing cells with high transcriptional activity).

What strategies can improve the success of co-immunoprecipitation experiments with RRP45 antibodies?

To improve co-immunoprecipitation with RRP45 antibodies:

• Stabilize protein-protein interactions: Add crosslinkers like DSP or formaldehyde (0.1-0.5%) to preserve transient interactions. RNA-dependent interactions may require RNase inhibitors.

• Adjust lysis conditions:

  • Test different detergents (NP-40, Triton X-100, CHAPS) at various concentrations

  • Optimize salt concentration (100-300 mM NaCl) to balance complex integrity with specificity

  • Consider adding glycerol (5-10%) to stabilize protein complexes

• Pre-conjugate antibodies: Directly conjugate RRP45 antibodies to beads before immunoprecipitation to reduce background.

• Sequential immunoprecipitation: Perform tandem immunoprecipitation using antibodies against different exosome components to increase purity.

• Scale optimization: Increase starting material for detection of substoichiometric interactions.

• Elution strategies: Compare different elution methods (glycine pH 2.5, SDS, peptide competition) for optimal complex recovery.

Previous studies successfully identified RNA exosome complex components in association with AID using a combination of immunoprecipitation approaches, demonstrating that optimized co-IP can reveal biologically significant interactions .

How can I use RRP45 antibodies to study the tissue-specific functions of the RNA exosome?

To investigate tissue-specific functions of the RNA exosome using RRP45 antibodies:

• Tissue-specific conditional knockout models: Generate animal models with tissue-specific RRP45 deletion to assess phenotypic consequences.

• Single-cell approaches: Combine RRP45 immunostaining with single-cell RNA-seq to correlate expression levels with cell-type-specific transcriptomes.

• Tissue microarrays: Use immunohistochemistry with RRP45 antibodies across multiple tissue types to assess expression patterns.

• Cell type-specific interactome: Perform BioID or APEX2 proximity labeling with RRP45 in different cell types to identify tissue-specific interaction partners.

• Disease-relevant tissues: Focus on tissues where RNA exosome mutations cause pathology, such as the nervous system, bone, or immune cells.

• Developmental timing: Analyze RRP45 expression and localization during development to identify critical periods of requirement.

The RNA exosome appears to have specialized functions in certain tissues. For example, B lymphocytes utilize the RNA exosome for antibody diversification through class switch recombination, as demonstrated by impaired CSR in cells with reduced levels of RNA exosome components .

What cutting-edge approaches can be combined with RRP45 antibodies for RNA metabolism studies?

Cutting-edge approaches that can be combined with RRP45 antibodies include:

• CLIP-seq variants:

  • iCLIP (individual-nucleotide resolution CLIP)

  • PAR-CLIP (Photoactivatable Ribonucleoside-Enhanced CLIP)

  • eCLIP (enhanced CLIP)
    These techniques can identify RNA binding sites of RRP45-containing complexes with nucleotide resolution.

• Nascent RNA sequencing:

  • NET-seq (Native Elongating Transcript sequencing)

  • TT-seq (Transient Transcriptome sequencing)
    Combined with RRP45 depletion, these approaches can identify co-transcriptional RNA processing events dependent on the RNA exosome.

• Live-cell imaging:

  • MS2/PP7 tagging of RRP45 targets

  • CRISPR-based RNA tracking
    These methods can visualize RRP45-dependent RNA processing in real-time.

• Proximity labeling:

  • APEX-seq for RNA proximity labeling

  • RBR-ID (RNA-binding region identification)
    These techniques can identify RNAs in proximity to RRP45-containing complexes in living cells.

• Cryo-EM: High-resolution structural analysis of RRP45 within the RNA exosome complex bound to various substrates and cofactors.

• Massively parallel reporter assays: Test thousands of RNA sequences for susceptibility to RRP45-dependent processing or degradation.

These advanced approaches can provide unprecedented insights into the mechanisms and targets of RRP45 within the RNA exosome complex.

How can computational approaches complement experimental studies with RRP45 antibodies?

Computational approaches that can enhance RRP45 antibody-based studies include:

• Structural modeling and simulations:

  • Molecular dynamics simulations to predict effects of mutations

  • Protein-protein docking to predict interactions with cofactors

  • RNA-protein docking to model substrate interactions

• Machine learning approaches:

  • Prediction of RNA features that determine exosome targeting

  • Classification of exosome substrates based on sequence/structure

  • Integration of multi-omics data to identify regulatory networks

• Network analysis:

  • Construction of RRP45-centered protein-protein interaction networks

  • RNA-protein interaction networks to identify functional modules

  • Pathway enrichment to identify biological processes

• Evolutionary analysis:

  • Comparative genomics to identify conserved functional domains

  • Analysis of selection pressure on different RNA exosome components

  • Co-evolution analysis to predict functional interactions

• Integrative multi-omics:

  • Integration of ChIP-seq, RNA-seq, and proteomics data

  • Correlation of RRP45 binding with RNA stability and processing outcomes

  • Identification of condition-specific regulation

Computational approaches can guide experimental design, help interpret complex datasets, and generate testable hypotheses about RRP45 function within the RNA exosome complex.

What are the implications of RRP45 in disease pathogenesis and potential therapeutic approaches?

Emerging research on RRP45 and disease pathogenesis suggests several important directions:

• Neurodevelopmental disorders: RNA exosome mutations have been linked to neurodevelopmental disorders. Studying RRP45's role in neural development and function could provide insights into pathogenesis.

• Cancer biology: Alterations in RNA processing are common in cancer. A missense mutation in the RNA exosome cap subunit gene EXOSC2 was identified in a multiple myeloma patient , suggesting potential roles for the RNA exosome in cancer development.

• Immune dysregulation: Given the role of the RNA exosome in antibody diversification , dysregulation might contribute to immune deficiencies or autoimmunity.

• Therapeutic targeting strategies:

  • Antisense oligonucleotides to modulate specific RNA exosome targets

  • Small molecule modulators of RNA exosome activity

  • Gene therapy approaches for genetic disorders caused by exosome defects

• Biomarker development: RRP45 expression or localization patterns might serve as diagnostic or prognostic biomarkers in conditions involving RNA metabolism dysregulation.

• Personalized medicine approaches: Genetic testing for RNA exosome mutations could guide targeted therapies for affected individuals.

Understanding the tissue-specific consequences of RNA exosome dysfunction and the precise molecular mechanisms involved will be crucial for developing effective therapeutic approaches.